3DMedNet is a community site that unites the diverse 3D printing in medicine community, seeking to educate and inspire to help this exciting field move forward at an even faster rate.
On 3DMedNet, you can find expert opinion and insight, and exclusive peer-reviewed journal articles, as well as the latest news and advances. Every application for 3D printing in medicine and healthcare is covered, including 3D printed pharmaceuticals, prosthetics, implants, medical devices and bioprinted tissue as well as resources for conducting 3D printing yourself.
About the Journal of 3D Printing in Medicine
As well as aiming to encourage interaction and discussion within the 3D printing in medicine and healthcare community, 3DMedNet aims to direct key information to members of the community. We are therefore partnered with the Journal of 3D Printing in Medicine, bringing you exclusive free access to select content from this exciting new publication.
The Journal of 3D Printing in Medicine (ISSN: 2059-4755) is a peer-reviewed journal from the progressive STM publisher, Future Science Group (FSG): publisher of titles such as Regenerative Medicine, RegMedNet and Nanomedicine.
Headed by Editor-in-Chief, Professor Dietmar W Hutmacher (Queensland University of Technology, Australia), the journal encompasses all aspects of 3D bioprinting and printing of relevance to medicine, including diverse areas such as implants and prosthetics; surgical guides; tissue engineering; pharmaceutical research and fabrication; and regulatory and safety issues. Full information on the journal’s Aims & Scope is available on the website, along with details of its expert international Editorial Board.
The Journal of 3D Printing in Medicine operates a double-blind peer review system, and ensures that all original research and review articles are assessed by a minimum of three experts, thereby reflecting FSG’s commitment to high-quality scholarly publications.
For more details please see here. Furthermore, submissions are being accepted via the journal’s online submission site. Alternatively, authors are invited to direct any article proposals or general queries to the Managing Editor, Adam Price-Evans.
About Future Science Group
Future Science Group, founded in 2001, is independently owned. Future Science Group’s portfolio consists of two imprints, Future Medicine and Future Science. Both publish books and journals. In addition to this core publishing business, Future Science Group develops specialist community-driven websites. Key titles and sites include Oncology Central, RegMedNet and the award-winning Regenerative Medicine.
The aim of Future Science Group is to serve the advancement of clinical practice and drug research by enhancing the efficiency of communication among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards.